Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation [0.03%]
小细胞肺癌的生物学、转化科学和临床创新
Shrey Sindhwani,Miles Thomas,Kanika Gehlaut et al.
Shrey Sindhwani et al.
Small-cell lung cancer (SCLC) is widely considered one of the most aggressive human malignancies, characterized by development of rapid metastases and eventual resistance to platinum chemotherapy and immunotherapy. For decades, despite rigo...
Aisling McGuigan
Aisling McGuigan
Lunsotogene parvec (lunsotogene parvec-cwha; OTARMENI™) is a dual adeno-associated virus (AAV) gene transfer therapy developed by Regeneron Pharmaceuticals for the treatment of profound, congenital hearing loss caused by OTOF variants. Del...
Aisling McGuigan
Aisling McGuigan
Acoziborole (Acoziborole Winthrop), a single-dose, oral antiprotozoal agent, has been developed by Drugs for Neglected Diseases initiative (DNDi), Sanofi and partners for the treatment of human African trypanosomiasis due to Trypanosoma bru...
DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives [0.03%]
靶向DLL3的晚期前列腺癌治疗策略：现有证据和未来展望
Giovanna Pecoraro,Alberto De Giorgi,Giulia Montelatici et al.
Giovanna Pecoraro et al.
Inhibition of androgen receptor (AR) signaling remains the cornerstone of systemic therapy for advanced prostate cancer (PC). However, a subset of aggressive tumors either arises de novo with neuroendocrine features or emerges under treatme...
Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2- Advanced Breast Cancer [0.03%]
针对HR+/HER2-晚期乳腺癌PI3K/AKT/mTOR途径的新兴策略
Lan Lei,Madison Canning,Elizabeth Sakach et al.
Lan Lei et al.
Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for approximately 70% of breast cancer cases. Despite recent advances with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), r...
Balancing Act: The Dual Roles of BAFF in Systemic Lupus Erythematosus [0.03%]
B细胞活化因子的双重作用：在系统性红斑狼疮中的双刃剑效应
Jhonatan Antonio Álvarez-Gómez,Daniel Appelgren,Tomas Walhelm et al.
Jhonatan Antonio Álvarez-Gómez et al.
In systemic lupus erythematosus (SLE) and other autoimmune diseases, B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) play critical roles through three receptors, i.e., BAFF-Receptor (BAFF-R), transmembrane activa...
Matt Shirley
Matt Shirley
Orforglipron (Foundayo™) is an orally administered, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist being developed by Eli Lilly and Co. for use in long-term weight management and for the treatment of type 2 diabetes (T2D) amo...
Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections [0.03%]
长效脂肽糖肽类治疗侵袭性革兰氏阳性菌感染
Madison E Salam,Daniel B Chastain,Douglas Fish et al.
Madison E Salam et al.
Gram-positive infections continue to pose a therapeutic challenge owing to their invasive nature (e.g., Staphylococcus aureus and Streptococcus pyogenes) and eradication difficulties (e.g., methicillin-resistant Staphylococcus aureus [MRSA]...
Comparative Efficacy of Non-opioid Analgesic Drugs for Chronic Cancer Pain: A Bayesian Network Meta-analysis [0.03%]
非阿片类镇痛药治疗慢性癌痛疗效的贝叶斯网络meta分析
Sebastiano Mercadante,Giovanbattista Vizzini,Alessio Lo Cascio
Sebastiano Mercadante
Purpose: While opioids remain the primary pharmacological intervention for cancer pain management, their clinical utility is frequently compromised by dose-limiting toxicities. This study aimed to determine the comparativ...
Matt Shirley
Matt Shirley
Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor agonist being developed by Sciwind Biosciences for the treatment of type 2 diabetes mellitus (T2DM) and for use in long-term weight manag...